Global AI in Genomics Market Outlook to 2028

Global AI in Genomics Market Overview

In 2023, the Global AI in Genomics market reached a valuation of USD 650 million, driven by advancements in AI and big data analytics, which facilitate rapid genomic data analysis. Increased investment in personalized medicine and the rising prevalence of genetic disorders have also fueled market growth.

The market is dominated by key players such as IBM, Microsoft (Incl. Terra), NVIDIA and Illumina. These companies lead in innovation and have significant investments in AI and genomic research, providing advanced solutions for genetic analysis and precision medicine.

In 2023, IBM launched its Watsonx AI platform, a significant development in the AI industry. Watsonx aims to provide businesses with advanced AI tools and capabilities, enhancing data analysis, automation, and decision-making processes, thus driving innovation and efficiency across various sectors.

Global AI in Genomics Current Market Analysis

North America as dominant region: North America has established itself as the dominant region in the AI genomics market, driven by a strong infrastructure for technological innovation and a highly supportive regulatory environment. In 2024, the National Human Genome Research Institute (NHGRI) increased funding by $3.1 million to a total of $12.3 million for the Diversity Centers for Genome Research initiative. This initiative aims to establish Genomic Research Centers at Minority Serving Institutions (MSIs) to promote innovative research projects and interdisciplinary collaboration.

Europe as emerging region: Europe is rapidly emerging as a significant player in the AI genomics market, driven by collaborative efforts across countries and a growing focus on research and innovation. In 2021, Horizon Europe allocated 5 million specifically for research projects focused on understanding the benefits and risks of genome editing technologies, such as CRISPR, in agriculture. This funding is part of the EU's broader 'Farm to Fork' strategy, which aims to enhance food sustainability and reduce environmental impacts.

USA as dominant country: The United States stands as the dominant country in the AI genomics market, driven by its unparalleled capacity for innovation and significant investment in healthcare technology. In March 2022, the Centers for Disease Control and Prevention (CDC) announced a competitive cooperative agreement to establish the Pathogen Genomics Centers of Excellence (PGCoE) network in the U.S. This initiative aims to enhance genomic surveillance and research capabilities.

Global AI in Genomics Market Segmentation

The Global AI in Genomics market can be segmented based on several factors:

By Product Offering: The Global AI in Genomics market is segmented by product offerings into software and services. In 2023, software dominates the market due to its ability to integrate large-scale genomic data efficiently, provide advanced analytical tools, and enable rapid advancements in genomic research and personalized medicine. The flexibility and scalability of software solutions cater to the evolving needs of researchers and clinicians, making them a preferred choice over services.

By Technology: The Global AI in Genomics market is segmented by technology into machine learning and computer vision. In 2023, machine learning dominance is attributed to its superior capability in analyzing complex genomic data sets, identifying patterns, and making accurate predictions. Its applications in drug discovery, disease prediction, and personalized treatment plans leverage the vast amounts of data generated, driving its widespread adoption and dominance over other technologies like computer vision.

By Functionality: The Global AI in Genomics market is segmented by functionality into gene sequencing and gene editing and others. In 2023, gene sequencing dominates the market due to its fundamental role in understanding genetic variations and their implications in health and disease. The increasing demand for precise and comprehensive genomic information to inform research, diagnostics, and personalized medicine drives the prominence of gene sequencing technologies over other functionalities like gene editing.

Global AI in Genomics Market Competitive Landscape

Company
Headquarters
Establishment Year
Geographical Presence
IBM
Armonk, New York, The US
1911
175+ countries
Microsoft (Incl. Terra)
Redmond, Washington, The US
1975
110+ countries
NVIDIA
Santa Clara, California, The US
1993
100+ countries
Illumina
San Diego, California, The US
1998
20+ countries (for AI in Genomics)

Microsoft and Genoox Partnership: In 2024, Microsoft strengthened its position in the AI genomics market by partnering with Genoox. This collaboration leverages Microsoft's Azure AI platform to enhance Genoox's capabilities in genomic data analysis and interpretation, streamlining the process for healthcare providers and researchers.

NVIDIA's Collaboration with Ultima Genomics: NVIDIA announced a strategic collaboration with Ultima Genomics in 2024 to advance genomic sequencing technologies. This partnership focuses on utilizing NVIDIA's Generative AI Microservices (NVIDIA NIM) to accelerate drug discovery, medical technology innovations, and digital health solutions, enhancing the efficiency and accuracy of genomic research.

Illumina's Acquisition of GRAIL and Emedgene: In 2023, Illumina completed the acquisition of GRAIL and Emedgene, significantly expanding its capabilities in early cancer detection and genomic data analysis. This strategic move allowed Illumina to integrate GRAIL's liquid biopsy technology with Emedgene's AI-driven genomic interpretation platform, bolstering its portfolio in precision medicine and personalized healthcare.

Global AI in Genomics Industry Analysis

Global AI in Genomics Market Growth Drivers:

Increasing Investment in Genomic Research: The Global AI in Genomics market is witnessing significant growth driven by substantial investments in genomic research. In 2024, the National Institutes of Health (NIH) allocated USD 1.8 billion for genomic studies, emphasizing the development of AI tools for genetic analysis and precision medicine. This influx of funding enhances research capabilities, accelerates technological advancements, and promotes the integration of AI in genomics, thereby driving market growth.

Rising Prevalence of Genetic Disorders: The increasing prevalence of genetic disorders globally is a major driver for the AI genomics market. According to the World Health Organization (WHO), over 300 million people worldwide suffer from rare genetic diseases in 2024. This growing patient population necessitates advanced diagnostic and therapeutic solutions, leading to heightened adoption of AI in genomics to identify genetic mutations and develop targeted treatments.

Advancements in AI and Big Data Analytics: The continuous advancements in AI and big data analytics are propelling the AI genomics market. In 2024, tech giants like IBM and NVIDIA invested USD 1.2 billion in AI-driven genomic research and development. These advancements enable the analysis of large-scale genomic datasets, improve diagnostic accuracy, and facilitate the development of personalized medicine, thereby fueling market growth.

Global AI in Genomics Market Challenges:

Data Inconsistency and Lack of Harmonization: The global AI in genomics market faces significant challenges due to data inconsistency arising from diverse experimental techniques and methodologies. Differences in nucleic acid extraction, NGS instrument models, and other factors contribute to non-uniform data, making it difficult to achieve comparable results across various sites and experiments, especially in decentralized settings.

Data Privacy and Security Concerns: Handling sensitive genomic data involves significant ethical and privacy challenges, requiring robust data protection measures. Compliance with stringent regulations such as GDPR and HIPAA is essential to safeguard patient information, but it also adds complexity and cost to the deployment of AI solutions in genomics, potentially hindering their widespread adoption.

Global AI in Genomics Future Market Outlook

By 2028, the Global AI in Genomics market is projected to reach USD 4 Bn, driven by continuous technological advancements and increased adoption of AI in healthcare. The future of the market will be shaped by innovations in AI algorithms, improved data integration, and expanded applications in disease diagnosis, drug discovery, and personalized medicine.

Future Market Trends

Expansion of AI Genomics in Clinical Diagnostics: By 2028, the application of AI in clinical diagnostics is expected to expand significantly, driven by continuous technological advancements and increasing demand for accurate and timely disease detection. AI-powered genomic tools will play a crucial role in identifying genetic mutations and predicting disease risks, leading to improved diagnostic outcomes and personalized treatment plans.

Growth in Personalized Medicine: The future of the AI genomics market will be shaped by the growing emphasis on personalized medicine. Over the next five years, AI-driven genomic analysis will enable healthcare providers to develop tailored treatment plans based on individual genetic profiles. This approach will improve therapeutic efficacy and patient outcomes, driving the adoption of AI in genomics and transforming healthcare delivery.

Please Note: It will take 5-7 business days to complete the report upon order confirmation